Pharmaceutical Industry News

In January 2018, doctors at the Ella Lemelbaum Institute for Immuno-Oncology at Sheba Medical Center implemented a breakthrough protocol for ovarian cancer.

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced the strengthening of its intellectual property (IP) portfolio, as it has successfully passed the patent opposition period in Europe..

Keystone Folding Box Co., a designer and cGMP manufacturer of paperboard packaging solutions, has developed a modified, customizable version of its Ecoslide-RX prescription blister package to address the nation's ongoing opioid epidemic.

The availability of, and demand for, at-home diagnostic products is on the rise – the market for point-of-care diagnostics is projected to reach $37 billion by the end of 2021.

Evoqua Water Technologies Corp. has completed an exclusive sales and distribution agreement with Horizon Solutions, LLC (“Horizon”) to expand local service in Puerto Rico.

The NSW Medical Device Fund has awarded AUD$500,000 to Indee Labs to partner with the University of Sydney to trial its technology to manufacture curative therapeutics for blood cancer.

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) reported today the first participant's initial visit in a pivotal clinical efficacy Phase 3 trial of the M-001 universal flu vaccine candidate.

Physicians are now able to successfully implant a new bio-absorbable, internal radiation treatment known as CivaSheet® to treat a patient with recurrent lung cancer. Approximately 234,000 patients per year in the U.S. are diagnosed with lung cancer, and of those, approximately 30% to 55% of patients with non-small cell lung cancer develop recurrence.

ARTMS Products today announced it received CE marking approval for its first-in-class, advanced technology QUANTM Irradiation System™ for producing high-value radioisotopes, such as Tc-99m and Ga-68, on medical cyclotrons.

Tilray Inc., a global pioneer in medical cannabis production and distribution, is pleased to announce that a study featuring Tilray 2:100, a medical cannabis oil containing high amounts of cannabidiol (CBD) and conservative amounts of tetrahydrocannabinol (THC), has shown promising results for children with drug-resistant epilepsy (DRE) due to Dravet Syndrome.